Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-DOTA-trastuzumab
- Development stage
- Phase 4
- Lead developer
- City of Hope Comprehensive Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-DOTA-trastuzumab is an investigational radiopharmaceutical diagnostic agent used for positron emission tomography (PET) imaging. It consists of the monoclonal antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2), conjugated to the positron-emitting radioisotope copper-64 (64Cu) via the DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator. The agent is designed to non-invasively visualize and quantify HER2 expression in tumors, helping to identify HER2-positive lesions in patients with breast or gastric cancer. It is particularly useful for detecting metastases, including those in the brain, and for predicting patient response to HER2-targeted therapies such as ado-trastuzumab emtansine (T-DM1) or trastuzumab deruxtecan (T-DXd) by assessing the biodistribution and tumor uptake of the antibody.
- Other names
- copper Cu 64-DOTA-trastuzumab64Cu-tetra-azacyclododecanetetra-acetic acid-trastuzumab64Cu-DOTA-trastuzumab PET
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 64Cu-DOTA-trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-DOTA-trastuzumab.